CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid derived sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Jitschin, Regina, Saul, Domenica, Braun, Martina, Tohumeken, Sehmus, Völkl, Simon, Kischel, Roman, Lutteropp, Michael, Dos Santos, Cedric, Mackensen, Andreas, Mougiakakos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217777/
https://www.ncbi.nlm.nih.gov/pubmed/30396365
http://dx.doi.org/10.1186/s40425-018-0432-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217777/
https://www.ncbi.nlm.nih.gov/pubmed/30396365
http://dx.doi.org/10.1186/s40425-018-0432-9

Ejemplares similares